Stellar Biotechnologies saw revenues increase 130 percent during the first quarter of 2016 but the company still lost more money in 2016 than it did during the same quarter of 2015. The Port Hueneme-based company reported first quarter 2016 results after markets closed Feb. 8. Stellar makes a protein for immunotherapy treatments using a unique Read More →
Port Hueneme-based Stellar Biotechnologies started trading on the Nasdaq stock exchange Nov. 5. Stellar makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Shares opened at $8.74 on Nov. 5 and were trading on the Nasdaq at $9.40 as of 11:30 Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Port Hueneme-based Stellar Biotechnologies has closed a $12 million round of financing and acquired a license for what could one day be its first drug. Stellar gained notoriety in the research world by snatching up a facility inside the Port of Hueneme gates during a round of base closings in the late 1990s. It used Read More →